CBER 510(k) Increase In FY 1999 Likely; Review Times Parallel FY 1998
This article was originally published in The Gray Sheet
Executive Summary
FDA's Center for Biologics Evaluation and Research has taken first action within 90 days of receipt on only nine of 25 traditional and abbreviated 510(k)s received so far during fiscal year 1999, according to a June 1 report developed by the center's Office of Blood Research and Review.
You may also be interested in...
CBER Cuts Device Review Backlog to 17% - Device Action Plan Update
FDA's Center for Biologics Evaluation and Review has taken first action within the statutory timeframe on 11 medical device premarket submissions received in the past six months.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”